Do you want to read an article? Please log in or register.
A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment®MMX® for active, mild-to-moderate ulcerative colitis
Inflammatory Bowel Disease
Related content
Inflammatory Bowel Disease
Use, effectiveness and tolerability of budesonide-MMX in ulcerative colitis: A real-life experience
United European Gastroenterol J.
Maconi G, Mezzina N, Landi S, Grillo S, Bezzio C, Bosani M, Pastorelli L, Dell'Era A, Chibbar R, Carmagnola S, Molteni P, Cassinotti A, Massari A, Ardizzone S
doi: 10.1177/2050640619864257.
Inflammatory Bowel Disease
Colectomy Rates in Ulcerative Colitis are Low and Decreasing: 10-year Follow-up Data From the Swiss IBD Cohort Study
J Crohns Colitis.
Parragi L, Fournier N, Zeitz J, Scharl M, Greuter T, Schreiner P, Misselwitz B, Safroneeva E, Schoepfer AM, Vavricka SR, Rogler G, Biedermann L; Swiss IBD Cohort Study Group
doi: 10.1093/ecco-jcc/jjy040.
Inflammatory Bowel Disease
Segmental colectomy for ulcerative colitis: is there a place in selected patients without active colitis ? An international multicentric retrospective study in 72 patients
J Crohns Colitis.
Frontali A, Cohen L, Bridoux V, Myrelid P, Sica G, Poggioli G, Espin E, Beyer-Berjot L, Laharie D, Spinelli A, Zerbib P, Sampietro G, Frasson M, Louis E, Danese S, Fumery M, Denost Q, Altwegg R, Nancey S, Michelassi F, Treton X, Panis Y
doi: 10.1093/ecco-jcc/jjaa107.
Inflammatory Bowel Disease
Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses
Lancet Gastroenterol Hepatol.
Nguyen NH, Fumery M, Dulai PS, Prokop LJ, Sandborn WJ, Murad MH, Singh S
doi: 10.1016/S2468-
Inflammatory Bowel Disease
Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort-An Epi-IBD Study
J Crohns Colitis.
Burisch J, Katsanos KH, Christodoulou DK, Barros L, Magro F, Pedersen N, Kjeldsen J, Vegh Z, Lakatos PL, Eriksson C, Halfvarson J, Fumery M, Gower-Rousseau C, Brinar M, Cukovic-Cavka S, Nikulina I, Belousova E, Myers S, Sebastian S, Kiudelis G, Kupcinskas L, Schwartz D, Odes S, Kaimakliotis IP, Valpiani D, D'Incà R, Salupere R, Zammit SC, Ellul P, Duricova D, Bortlik M, Goldis A, Kievit HAL, Toca A, Turcan S, Midjord J, Nielsen KR, Andersen KW, Andersen V, Misra R, Arebi N, Oksanen P, Collin P, de Castro L, Hernandez V, Langholz E, Munkholm P1, Epi-IBD Group
doi: 10.1093/ecco-jcc/jjy154.
RECOMMENDED
Inflammatory Bowel Disease
Real-World Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multi-Centre UK Experience
★ 3
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
doi: 10.1093/ecco-jcc/jjaa075.
Inflammatory Bowel Disease
A Phase 1b safety study of SER-287, a spore-based microbiome therapeutic, for active mild to moderate ulcerative colitis
Gastroenterology.
Henn MR, O'Brien EJ, Diao L, Feagan BG, Sandborn WJ, Huttenhower C, Wortman JR, McGovern BH, Wang-Weigand S, Lichter DI, Chafee M, Ford CB, Bernardo P, Zhao P, Simmons S, Tomlinson A, Cook D, Pomerantz R, Misra BK, Auninš JG, Trucksis M
doi: 10.1053/j.gastro.2020.07.048.
Inflammatory Bowel Disease
Golimumab effectiveness and safety in clinical practice for moderately active ulcerative colitis
Eur J Gastroenterol Hepatol.
O'Connell J, Rowan C, Stack R, Harkin G, Parihar V, Chan G, Breslin N, Cullen G, Dunne C, Egan L, Harewood G, Leyden J, MacCarthy F, MacMathuna P, Mahmud N, McKiernan S, McNamara D, Mulcahy H, Murray F, O'Connor A, O'Toole A, Patchett S, Ryan B, Sheridan J, Slattery E, Doherty G, Kevans D
doi: 10.1097/MEG.
Inflammatory Bowel Disease
Validation of the "German Inflammatory Bowel Disease Activity Index (GIBDI)": An Instrument for Patient-Based Disease Activity Assessment in Crohn's Disease and Ulcerative Colitis
Z Gastroenterol.
Hüppe A, Langbrandtner J, Häuser W, Raspe H, Bokemeyer B
doi: 10.1055/a-0605-4080.